Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine

International Journal of Dermatology

Volumn 41, Issue 6, 2002, Pages 352-356

  Bouwhuis, Saskia A ^a   El Azhary, Rokea A ^a   McEvoy, Marian T ^a   Gibson, Lawrence E ^a   Habermann, Thomas M ^a   Witzig, Thomas E ^a   Pittelkow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ALPHA INTERFERON; BEXAROTENE; CLADRIBINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETRETINATE; METHOTREXATE; PREDNISONE; PURINE DERIVATIVE; RETINOID; VINCRISTINE;

ADULT; AGED; BEAM THERAPY; CANCER GRADING; CANCER STAGING; CELL COUNT; CHEMOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERYTHRODERMA; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; LEUKOCYTE COUNT; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOMA; MALE; MEDICAL RECORD; MORTALITY; NEUTROPENIA; PRURITUS; PUVA; RETROSPECTIVE STUDY; SEPSIS; SEZARY CELL; SEZARY SYNDROME; SKIN CARE; STAPHYLOCOCCUS INFECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SEZARY SYNDROME; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0036337272     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2002.01501.x     Document Type: Conference Paper

References (9)

1. Mycosis fungoides and the Sézary syndrome
2. Classification of cutaneous lymphomas
3. Cutaneous T-cell lymphoma: Update of treatment
4. Phase II trial of 2-Chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma
5. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders
6. Intermittent 2-hour infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas
7. 2-Chlorodeoxyadenosine treatment in the Sézary syndrome
8. History of the Sezary syndrome
9. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution